A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas.

Trial Profile

A Phase 1b Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
  • Indications Glioma
  • Focus Adverse reactions
  • Sponsors Advantagene
  • Most Recent Events

    • 10 Mar 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 20 Nov 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 24 Feb 2012 Planned End Date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top